Non-Sibling Hematopoietic Stem Cell Transplantation Using Myeloablative Conditioning Regimen in Children With Maroteaux-Lamy Syndrome: A Brief Report Publisher Pubmed



Behfar M¹ ; Dehghani SS¹ ; Rostami T¹ ; Ghavamzadeh A¹ ; Hamidieh AA¹ Show Affiliations
Source: Pediatric Transplantation Published:2017

Abstract

Maroteaux-Lamy syndrome is a rare inherited lysosomal storage disorder with a progressive course. HSCT is a curable option for treatment in these patients. The following report describes our experience in HSCT for three patients with Maroteaux-Lamy syndrome using non-sibling donors. All of the patients received the same myeloablative regimen consisting of intravenous busulfan, cyclophosphamide, and rabbit antithymocyte globulin. Patients underwent HSCT from haploidentical other-related (n=1), full-matched other-related (n=1), and one-locus-mismatched unrelated donor. Stem cell sources included bone marrow (n=1), peripheral blood (n=1), and cord blood (n=1). Currently, two patients who received transplant from other-related donors showed full engraftment and regression of the symptoms of the disease, while for the patient with unrelated cord blood donor, graft failure resulted in progression of the disease and death. The result of our study showed beneficial effects of HSCT even from heterozygote donor. Due to rarity of the disease, future multicenter studies are recommended to find the best treatment approaches based on the patients’ status. © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd